Murine neural stem cells model Hunter disease in vitro: Glial cell-mediated neurodegeneration as a possible mechanism involved

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Fusar Poli, E ^a,b   Zalfa, C ^a   D'Avanzo, F ^c   Tomanin, R ^c   Carlessi, L ^b   Bossi, M ^a   Rota Nodari, L ^a   Binda, E ^a   Marmiroli, P ^a   Scarpa, M ^c,d   Delia, D ^b   Vescovi, A L ^a,d,e   De Filippis, L ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e Azienda ospedaliera Santa Maria Terni   (Italy)

Author keywords

Glial cells; Hunter Syndrome; Lysosomal storage disorders; MPSII; Neural stem cells

Indexed keywords

IDURONATE 2 SULFATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL AGGREGATION; CELL DENSITY; CELL DIFFERENTIATION; CELL RENEWAL; CONTROLLED STUDY; ENZYME DEFICIENCY; GLIA CELL; HUMAN; HUMAN TISSUE; HUNTER SYNDROME; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOUSE; NERVE DEGENERATION; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REGULATORY MECHANISM; SUBVENTRICULAR ZONE;

ANIMALS; APOPTOSIS; BRAIN; CELL DIFFERENTIATION; GLYCOPROTEINS; LYSOSOMAL STORAGE DISEASES; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS II; NEURAL STEM CELLS; NEURODEGENERATIVE DISEASES; NEUROGLIA;

EID: 84889606037     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.430     Document Type: Article

References (34)

1. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50: V4-v12
2. Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011; 6: 72
3. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-Term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011; 13: 95-101
4. Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey. Genet Med 2011; 13: 102-109
5. Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giugliani R, et al. The role of enzyme replacement therapy in severe Hunter syndrome-An expert panel consensus. Eur J Pediatr 2012; 171: 181-188
6. Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, et al. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol Genet Metab 2012; 107: 122-128
7. Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 2010; 19: 4871-4885
8. Cardone M, Polito VA, Pepe S, Mann L, D'Azzo A, Auricchio A, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 2006; 15: 1225-1236
9. Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 2005; 102: 14777-14782
10. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007; 90: 329-337
11. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8: 465-473
12. Wraith JE. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2008; 97: 76-78
13. Tomanin R, Zanetti A, Zaccariotto E, D'Avanzo F, Bellettato CM, Scarpa M. Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. Acta Paediatr 2012; 101: 692-701
14. Givogri MI, Bottai D, Zhu HL, Fasano S, Lamorte G, Brambilla R, et al. Multipotential neural precursors transplanted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction. Dev Neurosci 2008; 30: 340-357
15. Lemonnier T, Blanchard S, Toli D, Roy E, Bigou S, Froissart R, et al. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Mol Genet 2011; 20: 3653-3666
16. Marshall GP 2nd, Reynolds BA, Laywell ED. Using the neurosphere assay to quantify neural stem cells in vivo. Curr Pharm Biotechnol 2007; 8: 141-145
17. Reynolds BA, Rietze RL. Neural stem cells and neurospheres-re-evaluating the relationship. Nat Methods 2005; 2: 333-336
18. Heuer GG, Skorupa AF, Prasad Alur RK, Jiang K, Wolfe JH. Accumulation of abnormal amounts of glycosaminoglycans in murine mucopolysaccharidosis type VII neural progenitor cells does not alter the growth rate or efficiency of differentiation into neurons. Mol Cell Neurosci 2001; 17: 167-178
19. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010; 90: 1383-1435
20. Polito VA, Cosma MP. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am J Hum Genet 2009; 85: 296-301
21. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006; 51: 187-199
22. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010; 285: 20423-20427
23. Ballabio A, Gieselmann V. Lysosomal disorders: From storage to cellular damage. Biochim Biophys Acta 2009; 1793: 684-696
24. Decker L, ffrench-Constant C. Lipid rafts and integrin activation regulate oligodendrocyte survival. J Neurosci 2004; 24: 3816-3825
25. Kazanis I, Lathia JD, Vadakkan TJ, Raborn E, Wan R, Mughal MR, et al. Quiescence and activation of stem and precursor cell populations in the subependymal zone of the mammalian brain are associated with distinct cellular and extracellular matrix signals. J Neurosci 2010; 30: 9771-9781
26. Chojnacki A, Mak G, Weiss S. PDGFRalpha expression distinguishes GFAP-expressing neural stem cells from PDGF-responsive neural precursors in the adult periventricular area. J Neurosci 2011; 31: 9503-9512
27. Fager G, Camejo G, Olsson U, Ostergren-Lunden G, Lustig F, Bondjers G. Binding of platelet-derived growth factor and low density lipoproteins to glycosaminoglycan species produced by human arterial smooth muscle cells. J Cell Physiol 1995; 163: 380-392
28. Garcia-Olivas R, Hoebeke J, Castel S, Reina M, Fager G, Lustig F, et al. Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans. Histochem Cell Biol 2003; 120: 371-382
29. Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y. Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci USA 2010; 107: 7886-7891
30. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 2004; 25: 252-262
31. Vescovi AL, Reynolds BA, Fraser DD, Weiss S. bFGF regulates the proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated CNS progenitor cells. Neuron 1993; 11: 951-966
32. Gritti A, Frolichsthal-Schoeller P, Galli R, Parati EA, Cova L, Pagano SF, et al. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci 1999; 19: 3287-3297
33. Carlessi L, De Filippis L, Lecis D, Vescovi A, Delia D. DNA-damage response, survival and differentiation in vitro of a human neural stem cell line in relation to ATM expression. Cell Death Differ 2009; 16: 795-806
34. Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 2001; 24: 675-680